Eterna Cash from 2010 to 2024
| ERNA Stock | USD 1.02 0.05 4.67% |
Cash | First Reported 2006-06-30 | Previous Quarter 5.1 M | Current Value 2.6 M | Quarterly Volatility 6.8 M |
Check Eterna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eterna Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 64.6 K, Other Operating Expenses of 20 M or Total Operating Expenses of 19.2 M, as well as many indicators such as Price To Sales Ratio of 133, Dividend Yield of 0.0018 or PTB Ratio of 4.42. Eterna financial statements analysis is a perfect complement when working with Eterna Therapeutics Valuation or Volatility modules.
Eterna | Cash |
Latest Eterna Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Eterna Therapeutics over the last few years. Cash refers to the most liquid asset of Eterna Therapeutics, which is listed under current asset account on Eterna Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Eterna Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Eterna Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Eterna Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eterna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Eterna Cash Regression Statistics
| Arithmetic Mean | 5,918,965 | |
| Geometric Mean | 4,676,811 | |
| Coefficient Of Variation | 72.54 | |
| Mean Deviation | 3,201,158 | |
| Median | 5,455,000 | |
| Standard Deviation | 4,293,855 | |
| Sample Variance | 18.4T | |
| Range | 15.6M | |
| R-Value | 0.29 | |
| Mean Square Error | 18.2T | |
| R-Squared | 0.08 | |
| Significance | 0.30 | |
| Slope | 277,523 | |
| Total Sum of Squares | 258.1T |
Eterna Cash History
Other Fundumenentals of Eterna Therapeutics
| Cash And Short Term Investments | ||
| Change In Cash | ||
| Other Cashflows From Financing Activities | ||
| Total Cash From Financing Activities |
Eterna Therapeutics Cash component correlations
Click cells to compare fundamentals
About Eterna Therapeutics Financial Statements
Eterna Therapeutics stakeholders use historical fundamental indicators, such as Eterna Therapeutics' Cash, to determine how well the company is positioned to perform in the future. Although Eterna Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Eterna Therapeutics' assets and liabilities are reflected in the revenues and expenses on Eterna Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Eterna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 7.6 M | 6.1 M | |
| Cash And Short Term Investments | 7.6 M | 6.1 M | |
| Change In Cash | -3.9 M | -4.1 M | |
| Other Cashflows From Financing Activities | 48.8 M | 51.2 M | |
| Total Cash From Financing Activities | 16.6 M | 17.4 M | |
| End Period Cash Flow | 7.6 M | 8 M | |
| Free Cash Flow | -20.4 M | -21.4 M | |
| Other Non Cash Items | -1.9 M | -1.8 M | |
| Total Cash From Operating Activities | -20.4 M | -21.4 M | |
| Begin Period Cash Flow | 11.4 M | 12 M | |
| Total Cashflows From Investing Activities | -42.3 K | -44.4 K | |
| Free Cash Flow Yield | (2.14) | (2.03) | |
| Operating Cash Flow Per Share | (3.84) | (4.03) | |
| Free Cash Flow Per Share | (3.84) | (4.04) | |
| Cash Per Share | 1.43 | 1.35 | |
| EV To Operating Cash Flow | (2.15) | (2.04) | |
| EV To Free Cash Flow | (2.15) | (2.25) | |
| Price To Operating Cash Flows Ratio | (0.47) | (0.45) | |
| Price To Free Cash Flows Ratio | (0.47) | (0.49) | |
| Cash Ratio | 1.15 | 0.96 | |
| Cash Conversion Cycle | 1.8 K | 1.9 K | |
| Operating Cash Flow Sales Ratio | (345.14) | (327.88) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.00 | 1.05 | |
| Cash Flow Coverage Ratios | (2.27) | (2.38) | |
| Price Cash Flow Ratio | (0.47) | (0.45) | |
| Cash Flow To Debt Ratio | (2.27) | (2.38) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out the analysis of Eterna Therapeutics Correlation against competitors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.